UC | CD | IBD-U | PSC-UC | AIP-UC | Control | |
---|---|---|---|---|---|---|
N | 24 | 15 | 10 | 4 | 3 | 9 |
Sex | ||||||
Male/female | 11/13 | 10/5 | 7/3 | 4/0 | 2/1 | 8/1 |
Age† | 41.0 (26.7–55.3) | 33.0 (27.0–39.0) | 36.5 (30.4–42.6) | 33.5 (24.8–42.2) | 49.0 (35.0–63.0) | 68.0 (62.3–70.7) |
Duration [years]† | 7.5 (3.2–11.8) | 1.0 (0–3.5) | 4.5 (0–9.0) | 8.0 (1.1–14.9) | 6.0 (2.5–8.5) | |
Disease types | ||||||
Proctitis | 6 (25.0%) | 2 (50.0%) | 2 (66.7%) | |||
Left-sided colitis | 7 (29.2%) | 0 (0%) | 1 (33.3%) | |||
Right-sided colitis | 0 (0%) | 2 (50.0%) | 0 (0%) | |||
Pancolitis | 11 (45.8%) | |||||
Ileitis | 4 (26.7%) | |||||
Ileocolitis | 7 (46.7%) | 4 (40%) | ||||
Colitis | 4 (26.7%) | 6 (60%) | ||||
Part of biopsy | ||||||
[R/S/D/T/A/I] | 14/7/2/1/0/0 | 1/2/1/2/4/5 | 2/1/1/0/3/3 | 1/1/0/0/2/0 | 2/1/0/0/0/0 | 6/1/0/0/2/0 |
Endoscopic index | ||||||
REI | 6.5 (5.0–8.0) | 5.0 (3.6–6.4) | 5.0 (2.5–7.5) | |||
SES-CD | 10.0 (7.5–12.5) | |||||
Treatment | ||||||
None | 1 | 2 | 3 | 0 | 1 | 9 |
5-ASA | 20 | 7 | 7 | 4 | 2 | 0 |
Corticosteroid | 5 | 1 | 1 | 2 | 1 | 0 |
Thiopurine | 1 | 0 | 1 | 0 | 1 | 0 |
Tacrolimus | 1 | 0 | 0 | 0 | 0 | 0 |
Anti-TNFα | 3 | 6 | 4 | 0 | 0 | 0 |